New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
06:07 EDTACORAcorda Therapeutics reports FDA issues CRL for Plumiaz
Acorda Therapeutics announced that the FDA has issued a Complete Response Letter, or CRL, for the New Drug Application for Plumiaz Nasal Spray for the treatment of people with epilepsy who experience cluster seizures. A CRL is a communication from the FDA that informs a company that their review of the NDA is complete and the application cannot be approved in its present form. The company is currently developing a response to address the items outlined in the letter.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
10:26 EDTACORAcorda Therapeutics management to meet with IS Group
Subscribe for More Information
October 30, 2014
06:42 EDTACORAcorda Therapeutics: More than 60% of new AMPYRA patients enroll in First Step
Subscribe for More Information
06:42 EDTACORAcorda Therapeutics backs FY14 R&D expense $60M-$70M
Subscribe for More Information
06:41 EDTACORAcorda Therapeutics reports Q3 Ampyra revenue $96.4M
Subscribe for More Information
06:14 EDTACORAcorda Therapeutics reports Q3 non-GAAP EPS 65c, may not be comparable to 5c
Subscribe for More Information
October 29, 2014
07:09 EDTACORAlkermes sees FY14 free cash flow $20M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use